Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364684 · ClinicalTrials.gov registry record · Phase 2
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05364684: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT05364684 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05364684, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. The investigators hypothesize that LUM-201 (Ibutamoren mesylate) will decrease intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy (1H-MRS).
Interventions
- DRUG LUM-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-08-10 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05364684
The ClinicalTrials.gov registry entry for NCT05364684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LUM-201 is the first listed.
NCT05364684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05364684 about?
NCT05364684 is a clinical study titled "The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease". Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form o...
What is the current status of trial NCT05364684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-08-10. Estimated completion is 2024-12-23.
What interventions are being tested in trial NCT05364684?
The interventions under investigation include: LUM-201 (DRUG).
Who is sponsoring clinical trial NCT05364684?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.